“…It diminishes the financial burden and potential complications of tissue biopsies, but also can be performed sequentially defining disease evolution. This concept in a liver process has been validated for liver fibrosis, by correlating the grade of liver fibrosis with plasma liver enzymes in multiple clinical trials, i.e., Fib-4 [ 21 , 22 , 23 , 24 , 25 , 26 , 27 ]. The MELD score (modeling for end-stage liver disease) predicts mortality at 90 days in patients listed for liver transplantation, and it is the standard for liver graft allocation in the US and abroad [ 28 , 29 , 30 ].…”